Boma Muteb P, Kaluila Mamba J F J, Muhau Pfutila P, Bilo V, Panda Mulefu J D, Diallo D A
Centre de référence de la drépanocytose de Lubumbashi (CRDL). Institut de recherche en sciences de la santé (IRSS), Lubumbashi, Congo.
Centre de référence de la drépanocytose de Lubumbashi (CRDL). Institut de recherche en sciences de la santé (IRSS), Lubumbashi, Congo, Centre de médecine mixte et d'anémie SS de Kinshasa (CMMASS). Institut de recherche en sciences de la santé, Kinshasa, (IRSS), Congo.
Med Sante Trop. 2017 Nov 1;27(4):387-391. doi: 10.1684/mst.2017.0719.
The partial exchange transfusions necessary for management of some sickle-cell complications raise the issue of effectiveness in the context of limited resources and inadequate blood safety. This study evaluated the effectiveness, safety, and cost of partial exchange transfusions in 39 patients with sickle-cell anemia in Lubumbashi, looking at the patients' age and gender and the tolerability and direct cost of the transfusions. Excel and SPSS 18 were used for data entry and analysis. Chi2 and Fisher exact tests were used for comparisons. A P-value ≤ 5% was considered statistically significant. The average age of patients was 8.6 ± 6.4 years, and the majority were girls. The most frequent indications were stroke, severe infections, severe vasooclusive crises, and acute chest syndrome. Partial exchange transfusions were effective in improving hemoglobin and hematocrit as well as the percentage of HbS. No acute accident was observed during any partial exchange transfusion; one anti-Kell alloimmunization and 2 cases of iron overload were observed. The annual cost of partial exchange transfusions per patient requiring (and able to afford) regular treatment was US $ 3,345 without iron chelation and more than US $ 5000 with chelation. Partial exchange transfusions are effective and tolerated, but financially inaccessible to the majority of our sickle cell patients. Thus, an assessment is needed of the economic burden of sickle cell complications that require partial exchange transfusions in the context of countries with limited financial resources.
对于某些镰状细胞并发症的治疗而言,必要的部分换血疗法在资源有限且血液安全不足的情况下引发了疗效问题。本研究评估了在卢本巴希对39例镰状细胞贫血患者进行部分换血疗法的有效性、安全性和成本,研究了患者的年龄和性别以及输血的耐受性和直接成本。使用Excel和SPSS 18进行数据录入和分析。采用卡方检验和Fisher精确检验进行比较。P值≤5%被认为具有统计学意义。患者的平均年龄为8.6±6.4岁,大多数为女孩。最常见的适应症是中风、严重感染、严重血管闭塞性危机和急性胸部综合征。部分换血疗法在提高血红蛋白、血细胞比容以及HbS百分比方面有效。在任何一次部分换血过程中均未观察到急性意外事件;观察到1例抗Kell同种免疫和2例铁过载。对于需要(且能够负担)定期治疗的患者,部分换血疗法的年成本在不进行铁螯合时为3345美元,进行螯合时超过5000美元。部分换血疗法有效且耐受性良好,但对于我们大多数镰状细胞病患者来说在经济上难以承受。因此,在财政资源有限的国家,需要评估需要部分换血疗法的镰状细胞并发症的经济负担。